BioCentury
ARTICLE | Clinical News

Halofuginone: Phase Ib/IIa suspended enrollment

February 1, 2016 8:00 AM UTC

Akashi suspended dosing and enrollment in all cohorts of the open-label, U.S. Phase Ib/IIa HALO trial in boys and young men with ambulatory or non-ambulatory DMD after 1 patient receiving once-daily 6...